Research & Education

New Therapies Are Coming for Malignant Pleural Mesothelioma - 14th Webinar: IASLC Lung Cancer Grand Rounds Series

Thursday, April 2, 2015 - Recording Available

 

   

Lee M. Krug, MD
Associate Attending Physician
Deputy Chief, Thoracic Oncology Service
Director, Mesothelioma Program
Memorial Sloan Kettering Cancer Center

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

 

Name of Planner(s): 

 

     Deb Whippen-Nothing to Disclose

Name of Activity: 

 

New Therapies Are Coming for Malignant Pleural Mesothelioma

Date of Activity:

 

04/02/2015

Faculty/Speaker(s):

 

Ramaswamy Govindan, MD  -Moderator -Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board.

Lee M. Krug, MD- Speaker Is:

PAID CONSULTANT:Morphotec, Merch, Sharpe, and Dohme

RESEARCH FUNDING: Eli Lilly, Genentech, MedImune, Bristol-Meyers Squibb, Verastem.

MEMBER OF: Mesothelioma Applied research Foundation

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

       Yes  

If yes, please list: Grant support from Bristol-Meyers Squibb, Celgene and Genentech.

 

IASLC is holding a LIVE WEBINAR featuring Dr. Lee Krug. This session will begin with a discussion regarding the current standard approach for evaluation and treatment of a patient with malignant pleural mesothelioma. We will then highlight a number of novel therapeutics that have yielded promising early results, and have the potential to impact the treatment of this disease in the very near future.

Following After viewing this program attendees will:

  • Recognize the current standard approach for evaluation and treatment of patients with malignant pleural mesothelioma.
  • Implement evolving management and treatment paradigms in mesothelioma.
  • Identify and discuss the major clinical trials now underway in mesothelioma.

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Krug via internet chat.

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

 

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

This session will begin with a discussion regarding the current standard approach for evaluation and treatment of a patient with malignant pleural mesothelioma. We will then highlight a number of novel therapeutics that have yielded promising early results, and have the potential to impact the treatment of this disease in the very near future.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

DOWNLOAD RECORDING

CME INFO:

IASLC Financial/Commercial and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

Location Local time Time zone UTC offset
New City (U.S.A. - New York) Thursday, April 2, 2015 at 9:00:00 PM EDT UTC-4 hours
Denver (U.S.A. - Colorado) Thursday, April 2, 2015 at 7:00:00 PM MDT UTC-6 hours
Chicago (U.S.A. - Illinois) Thursday, April 2, 2015 at 8:00:00 PM CDT UTC-5 hours
Los Angeles (U.S.A. - California) Thursday, April 2, 2015 at 6:00:00 PM PDT UTC-7 hours
São Paulo (Brazil - São Paulo) Thursday, April 2, 2015 at 10:00:00 PM BRT UTC-3 hours
Paris (France) Friday, April 3, 2015 at 3:00:00 AM CEST UTC+2 hours
Hong Kong (Hong Kong) Friday, April 3, 2015 at 9:00:00 AM HKT UTC+8 hours
Tokyo (Japan) Friday, April 3, 2015 at 10:00:00 AM JST UTC+9 hours
Corresponding UTC (GMT) Friday, April 3, 2015 at 01:00:00    

How to use the Time Zone Converter

This series is supported in part by unrestricted educational grants provided by Bristol-Myers Squibb Co., Celgene and Genentech